Expertise in
20
conditions

Dr. Christopher Bowlus

Gastroenterology
Office
4150 V St Ste 3500, 
Sacramento, CA 
Offers Telehealth
Expertise in
20
conditions
Office
4150 V St Ste 3500, 
Sacramento, CA 

Overview

Christopher Bowlus is a Gastroenterologist in Sacramento, California. Dr. Bowlus is highly rated in 20 conditions, according to our data. His top areas of expertise are Sclerosing Cholangitis, Primary Biliary Cholangitis, Cholangitis, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 169 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Hospital Affiliations

University Of California Davis Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
California Health And Wellness
  • MANAGED MEDICAID PLAN
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 13 Less Insurance Carriers -

Locations

Office
4150 V St Ste 3500, Sacramento, CA 95817
Other Locations
Midtown Ambulatory Care Center-Uc Davis Health
3160 Folsom Blvd Ste 3500, Sacramento, CA 95816

Additional Areas of Focus

Dr. Bowlus has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Unknown
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: Sulfasalazine
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 06, 2022
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients
Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients
Enrollment Status: Completed
Publish Date: June 11, 2019
Intervention Type: Other
An Open-Label Study Of Ursolic Acid For Primary Sclerosing Cholangitis
An Open-Label Study Of Ursolic Acid For Primary Sclerosing Cholangitis
Enrollment Status: Withdrawn
Publish Date: July 25, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

169 Total Publications

Nebokitug, an anti-CCL24 monoclonal antibody, in patients with primary sclerosing cholangitis: A phase 2 study.
Nebokitug, an anti-CCL24 monoclonal antibody, in patients with primary sclerosing cholangitis: A phase 2 study.
Journal: The American journal of gastroenterology
Published: July 28, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Valentina Medici
Gastroenterology
Expertise in
11
conditions
Dr. Valentina Medici
Gastroenterology

Midtown Ambulatory Care Center-Uc Davis Health

3160 Folsom Blvd Ste 3500, 
Sacramento, CA 
 (1.6 miles away)
916-734-8616
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Valentina Medici is a Gastroenterologist in Sacramento, California. Dr. Medici is highly rated in 11 conditions, according to our data. Her top areas of expertise are Wilson Disease, Gastroparesis, Gastric Dysmotility, Ileostomy, and Liver Transplant.

Expertise in
14
conditions
Dr. Joseph Leung
Gastroenterology
Expertise in
14
conditions
Dr. Joseph Leung
Gastroenterology

Office

4150 V St Ste 3500, 
Sacramento, CA 
 (0.4 miles away)
916-734-7224
Languages Spoken:
English
See accepted insurances

Joseph Leung is a Gastroenterologist in Sacramento, California. Dr. Leung is highly rated in 14 conditions, according to our data. His top areas of expertise are Cholestasis, Bile Duct Stricture, Bile Duct Obstruction, Colonoscopy, and Endoscopy.

Eric W. Chak
Expertise in
19
conditions
Dr. Eric W. Chak
Gastroenterology
Expertise in
19
conditions
Dr. Eric W. Chak
Gastroenterology

2068 John Jones Care Center

2068 John Jones Road, 1st Floor, 
Davis, CA 
 (17.3 miles away)
530-747-0389
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Chak is a Gastroenterologist in Davis, California. Dr. Chak is highly rated in 19 conditions, according to our data. His top areas of expertise are Hepatitis, Alcoholic Cirrhosis, Jaundice, Visceromegaly, and Endoscopy. Dr. Chak is currently accepting new patients.

Frequently Asked Questions about Dr. Christopher Bowlus

How do I make an appointment with Dr. Christopher Bowlus?

You can book an appointment with Dr. Christopher Bowlus by calling their office at 916-734-3751. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher Bowlus a top-rated expert for Sclerosing Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher Bowlus is classified as an Elite expert for Sclerosing Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher Bowlus specialize in?

While Dr. Christopher Bowlus is a Gastroenterology, they have specific expertise in Sclerosing Cholangitis, Primary Biliary Cholangitis, and Cholangitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Christopher Bowlus participate in research or clinical trials?

Yes. Dr. Christopher Bowlus has published 169 articles and abstracts on conditions like Sclerosing Cholangitis. You can view a list of Dr. Christopher Bowlus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christopher Bowlus accept my insurance?

Dr. Christopher Bowlus accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 916-734-3751 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bowlus's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile